initi coverag xeri overweight rate pt believ
gvoke compani recent launch ready-to-us rtu inject form
glucagon sever hypoglycemia insulin-depend diabet patient repres
far better option glucagon emerg kit histor avail
point believ product time play larg role drive
far greater prescript rx volum histor vastli under-
penetr space would view competit gvoke
baqsimi intranas spray form glucagon zero-sum game given realiti
under-penetrated natur space feedback survey physician reinforc
view believ gvoke peak sale excess realist translat
attract risk/reward profil context market cap
gvoke play major role paradigm shift regard sever hypoglycemia
rescu glucagon emerg kit histor avail
gener cumbersom use given requir mix dilut ideal
either self- caregiv administr context medic urgent situat
survey physician manag signific number insulin-depend
diabet patient respond note kit either moder
difficult patient caregiv use avail gvoke lilli
baqsimi respond poll note plan prescrib glucagon
product either moder significantli frequent pleas contact psc
sale person detail spreadsheet version survey
zero-sum game baqsimi gvoke injector pen hypopen drive
critic mass franchis bear mind near rx
written annual glucagon kit compar around insulin-depend type
type diabet patient indic vastli under-penetrated
space uncommon patients/caregiv simpli call case
sever hypoglycemia henc sanguin view regard competit survey
respond note plan prescrib gvoke injector pen anywher
slightli significantli frequent baqsimi anoth state
plan prescrib gvoke hypopen either frequent slightli less frequent
baqsimi half respond state plan prescrib
gvoke hypopen either slight major signific major insulin-
depend diabet patient feedback speak highli recept audienc
gvoke though clearli pen drive enthusiasm surpris given
pen gener patient-friendli pre-fil syring feedback also
speak sizabl role gvoke hypopen lilli baqsimi
risk includ competit payer risk associ gvoke
xeri leverag deliveri technolog develop optim form
ep disc
piper sandler seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
initi coverag xeri overweight rate pt repres
upsid current share price believ gvoke compani
recent launch ready-to-us rtu inject form glucagon sever hypoglycemia
insulin-depend diabet patient play major role drive far greater prescript rx
glucagon rescu product physician given repres far patient- caregiver-
friendli option glucagon emerg kit histor avail note
product leverag compani xerisol platform enabl creation rtu room
temperature-st liquid solut actual one two inject platform
xeriject primarili focus optim biolog formul pre-fil syring form
gvoke current avail injector pen form product known gvoke hypopen
set launch juli believ peak sale gvoke excess
realist potenti upsid target given compani explor label expans
opportun exercise-induc hypoglycemia eih insulin-depend diabet patient well
hypoglycemia post-bariatr surgeri set regard competit landscap
would view avail eli lilli baqsimi intranas spray form glucagon drive
zero-sum game vi -- vi gvoke given vast under-penetr glucagon rescu space
feedback survey physician reinforc view pt base
ep estim discount year support discount
cash flow dcf analysi see detail
vastli under-penetrated space set evolv dramat gener sens sever
hypoglycemia risk factor diabet patient insulin-depend insulin
product carri warn languag respect prescrib label regard risk
hypoglycemia major power insulin market novo nordisk distribut
glucagon emerg kit instanc novo nordisk glucagen hypokit lyophil powder
requir reconstitut kit histor home-bas option avail
glucagon rescu rel cumbersom patient caregiv use
fairli obviou given reconstitut requir context medically-urg
situat note around rx written annual glucagon kit per
iqvia compar around insulin-depend type type diabet patient
 per manag commentari indic vastli under-penetrated space
uncommon patients/caregiv simpli call case sever hypoglycemia
survey physician manag signific number insulin-depend diabet
patient respond note kit either moder difficult patient
caregiv use avail gvoke lilli baqsimi respond poll
note plan prescrib glucagon product either moder significantli
frequent point illustr estim annual prescript rx next-
gener glucagon product averag net realiz price per rx would translat
much glucagon rescu product net sale clear believ overal
 market size ultim well north even higher penetr glucagon
product realiti mani patient may administ north inject per year
physician feedback point ampl room gvoke lilli baqsimi co-exist
thrive commerci note gvoke pre-fil syring gain fda approv
septemb baqsimi gain fda approv juli launch august
baqsimi weekli rx run compar around begin
per iqvia would keep mind earli day term gvoke commerci
roll-out work drive payer access see detail believ
launch gvoke hypopen later year critic drive critic mass simpli
patient- caregiver-friendli option versu pre-fil syring overal believ
competit landscap prove zero-sum game physician survey
respond note plan prescrib gvoke hypopen anywher slightli
significantli frequent basqsimi anoth state plan prescrib
gvoke hypopen either frequent slightli less frequent baqsimi
half respond state plan prescrib gvoke hypopen either slight major
signific major insulin-depend type type diabet patient lastli
respond believ pen present either moder significantli better option
baqsimi nasal spray anoth believ pen either slightli better option
page
continu
good option rel baqsimi feedback view speak highli recept
audienc gvoke though clearli pen present drive enthusiasm
feedback also speak sizabl role gvoke hypopen lilli baqsimi
dovetail feedback cite point significantli greater rx glucagon product
given avail next-gener formul
signific progress payer front thought sale ramp note
support commerci gvoke sale forc rep target cde
certifi diabet educ physician current account glucagon
prescript regard price wholesal averag cost wac per gvoke syring
note wac basqsimi intranas spray single-us spray also
wac next-gener product gener similar wac current avail
glucagon emerg kit note month gvoke prefer unrestrict
access commerci plan encompass approxim commerci live
prefer unrestrict access medicar part plan encompass commerci live
bear mind product commerci avail sinc novemb
regard remain commerci live gvoke essenti either non-pref
posit without restrict non-pref posit restrict regard remain
medicar part live gvoke gener cover non-pref posit
drive greater access without
restrict importantli manag note contract place encompass
pre-fil syring present hypopen note model reflect
net sale translat rx grow net
sale rx estim account glucagon rescu rx
inclus baqsimi emerg kit
gvoke label expans opportun could significantli expand footprint
franchis particularli exercise-induc hypoglycemia set recent
announc encourag result evalu mini-dos gvoke prevent exercise-
induc hypoglycemia eih type diabet patient in-clin stage studi
patient exercis vigor specif incid eih higher patient placebo
plu reduct insulin pump standard-of-car soc vigor exercis set
popul rel patient gvoke dose mcg plu soc insulin pump
reduct data second stage studi evalu patient exercis home
expect later view attract expans opportun serv
widen footprint gvoke among insulin-depend diabet popul also bear mind
approv indic glucagon product regard post-bariatr surgeri
patient postprandi meal hypoglycemia episod risk factor
popul phase ii placebo-control studi in-clin set mini-dos gvoke
mcg standard adult dose diabet set mg self-administ
follow success meal challeng result restor normal blood glucos within
minut dose incid rebound hypoglycemia requir rescu oral
glucos tablet lower gvoke arm rel placebo data second part
studi conduct outsid clinic set expect later advanc phase
possibl end note model conserv reflect sale
impact potenti label expans though model reflect spend pivot
studi associ capit rais support develop
base price target ep estim time price-to-earnings multipl
discount five year believ logic year base
pt given better reflect steady-st profit compani steadi state growth
gvoke model total sale growth versu given runway
view transform earn growth long-term well beyond
believ price-to-earnings appropri note estim reflect contribut gvoke
expans set name sever hypoglycemia follow bariatr surgeri exercise-
induc hypoglycemia eih diabet patient lastli believ discount rate
adequ reflect commerci risk associ drive essenti paradigm shift
page
glucagon rescu space also adequ reflect clinic regulatori risk
associ develop gvoke indic current approv therapi
valuat support discount cash flow dcf analysi refer exhibit
detail dcf reflect gvoke sale total
world-wide sale model sale account total sale
case multiple-bas pt calcul employ discount rate midpoint
rang dcf believ discount rate adequ reflect xeriss mix commerci
clinical/regulatori risk
price
compani report factset psc estim
page
except per share multipl market p/erevenueev/revenuetickercompanypric peer exhibit
ev equiti valu per share calcul use termin growth rate top wacc left assumpt
includ cash cash equival short long term market secur includ net proce equiti offer
psc estim factset bloomberg compani report
summari psc estim
consensu estim
psc estim factset bloomberg compani report
page
free good gross margin develop gener incom depreci ebitda margin oper provis incom oper depreci capit increas net work cash valu cash valu growth cash cash termin valu per share outstand valu per million except per ex product product revenu consensu gener incom tax net outstand ep consensu
risk thesi
commerci risk despit fact gvoke oper vastli under-penetrated market
limit competit would keep mind compani need drive consider growth
underli glucagon market order achiev commerci success ultim
profit though view presenc lilli intranas product baqsimi
zero-sum game rel gvoke alway possibl lilli product could captur
lion share glucagon volum even grow underli market anoth consider
payer access need continu execut payer contract order drive
consider volum growth restrict payer landscap could limit extent gvoke
clinic regulatori risk relat gvoke expans opportun label expans
opportun gvoke may bear fruit bear mind xeri evalu
product indic current approv treatment exist given backdrop
certainli possibl pivot studi could fail yield adequ result glucagon
product test random clinic trial expans set name
bariatr surgeri patient eih diabet patient
financ risk xeri like need access addit capit potenti multipl time order
reach profit given rel promotion-sensit natur glucagon market
signific spend direct-to-consum campaign order drive greater patient awar
new glucagon rescu option current estim reflect xeri turn cash flow posit
end
xeri specialti pharmaceut compani leverag ready-to-us rtu liquid
inject infus formul technolog platform develop commerci treatment
variou diseas condit xeriss platform consist two differ technolog
xerisol platform focus inject liquid solut well-suit small molecul
peptid xeriject platform focus non-aqu solut dri powder
well-suit monoclon antibodi biolog
compani commerci portfolio consist gvoke first fda-approv rtu liquid form
glucagon subcutan sc inject treatment sever hypoglycemia product
commerci avail pre-fil syring form sinc novemb
expect launch injector pen version product juli note xeri vari
intellectu properti estat protect gvoke patent expir late
xerisol platform brief xeriss xerisol platform liquid inject technolog platform
best suit small molecul peptid technolog center around idea
develop aqueou small molecul peptid dri powder reconstitut
polar aprot liquid formul formul inject via subcutan
intramuscular administr use auto-injector pre-fil syring
xeriject platform brief xeriss xeriject platform focus non-aqu solut dri
powder best suit biolog protein monoclon antibodi vaccin
technolog function basi develop dri powder appropri dilut
highli concentr low-volum past formul product administ via
pump pen
page
background inject deliveri platform
glucagon hormon produc pancrea small peptid respons regul
glucos level blood specif drop blood glucos level elicit releas glucagon
pancrea signal liver convert glycogen glucos immedi releas
bloodstream insulin lower glucos level excess insulin limit bodi abil
produc glucagon result hypoglycemia blood glucos level mg/dl
common condit insulin-depend type type diabet patient mild case
hypoglycemia blood glucos mg/dl common treatment method
rais blood glucos consum carbohydr wait minut evalu
blood glucos level practic known rule case sever
hypoglycemia character xeri blood glucos less mg/dl mmol/l
accompani confus dizzi irrit unconsci seizur lead
brain damag even death emerg dose glucagon may requir histor
sever hypoglycem event glucagon administ home use glucagon emerg
background hypoglycemia
size glucagon market per manag commentari type diabet
patient experi episod sever hypoglycemia year type diabet
patient experi least one episod sever hypoglycemia blood glucos less mg/dl
mmol/l per year approxim type type diabet patient
page
 manag estim roughli insulin importantli around
insulin-depend patient per manag commentari fill prescript glucagon annual
larg due cumbersom natur glucagon emerg kit histor
avail see detail given backdrop believ signific
unmet need vastli underserv market patient- caregiver-friendli glucagon
administr option manag note base market research insulin-
depend type diabet patient insulin-depend type diabet patient
 risk experienc sever hypoglycemia event thu prescrib
gvoke repres transform option glucagon rescu view xeri recent
launch gvoke ready-to-us rtu subcutan inject form glucagon sever
hypoglycemia rescu insulin-depend diabet patient notabl gvoke first glucagon
product approv fda administ via pre-fil syring pen
injector gvoke hypopen form product approv septemb
form launch novemb xeri plan launch hypopen version juli see
detail note gvoke avail two dosag dose
pediatr patient weigh pound dose adolesc adult
patient weight lb addit gvoke avail packag either one two
devic product price pariti current avail glucagon emerg kit baqsimi
 wholesal acquisit cost wac per devic xeri also submit market
author applic gvoke european medicin agenc ema late
anticip eu approv
fda approv gvoke base result three phase studi patient type
diabet two crossov studi adult patient age patient receiv
gvoke glucagon kit gek either eli lilli kit novo nordisk glucagen hypokit
differ time point one pediatr studi age specif adult studi includ
clinic visit day apart patient random receiv mg gvoke
one visit mg gek visit primari endpoint studi
respond analysi defin blood glucos level reach mg/dl increas
blood glucos greater mg/dl within minut glucagon dose first double-
blind phase studi patient compar gvoke kit studi patient
respond receiv gvoke compar patient receiv kit
second double-blind studi compar gvoke novo nordisk glucagen hypokit studi
patient respond receiv gvoke compar patient receiv
glucagen hypokit note gvoke safe well toler studi
common advers event nausea vomit
three-arm pediatr studi patient two dose gvoke evalu base age
specif patient age administ mg dose gvoke two separ in-
patient visit patient age administ mg glucagon one visit mg
glucagon second visit blood glucos level fell mg/dl primari endpoint
respond analysi defin increas blood glucos level mg/dl
baselin follow gvoke inject note patient respond receiv
gvoke mean increas blood glucos mg/dl min inject mg/dl
min inject gvoke safe well toler studi common
advers event nausea hypoglycemia vomit
page
mean glucos level phase pediatr studi
summari phase data gvoke
compani report psc estim
avail next-gener formul
glucagon rescu kit clearli limit recal roughli insulin-
depend type type diabet patient around patient fill
prescript glucagon rescu product annual per manag commentari
page
gvoke glucagon emerg kit gek gvoke glucagon hypokitgvok pediatr patientsclin studi patient type diabet particip crossov studi involv two clinic visit patient randomli assign gvoke one session eli lilli kit second patient type diabet particip crossov studi involv two clinic visit patient randomli assign gvoke one session novo nordisk glucagen hypokit second pediatr patient type diabet particip crossov studi involv two clinic visit patient age treat gvoke administr insulin induc state hypoglycemia dose mg mg mg glucagon patient age mg first visit mg second visit patient age endpointrespond analysi defin achiev blood glucos level mg/dl increas blood glucos mg/dl within min glucagon dosingrespond analysi defin achiev blood glucos level mg/dl increas blood glucos mg/dl within min glucagon dosingrespond analysi defin increas blood glucos mg/dl within min glucagon dosingsecondari endpointsecondari endpoint supportivesecondari endpoint supportivesecondari endpoint supportivetreat success gvoke gek successgvok gek successadvers event nausea pain
larg function cumbersom natur glucagon emerg kit histor
avail specif glucagon kit contain mg glucagon lyophil glucagon powder
singl dose vial ml diluent provid separ pre-fil syring note mg
dose glucagon recommend patient weigh pound lb mg dose
recommend pediatr patient weigh lb dose patient lb requir
measur withdraw half mg glucagon solut discard unus portion
prior ad diluent remain mg certainli ideal paradigm rescu
situat note kit product administ via intraven intramuscular
illustr glucagon kit compon part
note eli lilli glucagon emerg kit novo nordisk glucagen hypokit
commerci avail year despit continu growth diabet market
overal glucagon rx volum flat past year specif glucagon kit
rx essenti flat increas less versu declin
versu also declin compar interestingli rx volum
glucagon kit grew versu avail next-gener formul
far patient- caregiver-friendli envis paradigm shift drive
signific growth overal glucagon market next year
detail initi baqsimi volum trend believ look initi rx data eli lilli
baqsimi provid window landscap glucagon product chang recal
baqsimi intranas powder formul glucagon becam commerci avail
page
 juli product also approv eu octob baqsimi singl
fix dose mg glucagon administ one nostril hypoglycemia rescu
treatment second dose may administ minut respons observ like
gvoke product packag one-pack two-pack price pariti current
avail glucagon emerg kit wac per devic note baqsimi
approv patient diabet four year older recal gvoke approv patient
two year older addit half baqsimi rx written sinc launch written
two pack glucagon option around devic per rx februari
given backdrop coupl fact baqsimi first glucagon rescu product
novel formulation/deliveri profil launch believ strong initi volume/sal trend
baqsimi bode well gvoke particularli gvoke hypopen specif
rx written baqsimi product first full quarter market per iqvia
week end product week third parti rx data weekli rx baqsimi
run compar rx around begin rx
show quarter-to-f sequenti growth rate versu correspond period
note report baqsimi sale eu sale
baqsimi sale prescript volum
present iqvia
page
keep close eye hypopen alreadi approv fda like main
driver signific traction gvoke franchis recal xeriss pen injector form
gvoke approv fda septemb alongsid pre-fil syring form expect
launch juli note hypopen launch consider later
pre-fil syring form due constraint relat commerci scale
gvoke auto-injector pre-fil syring manufactur suppli pyramid
laboratori manag note pyramid laboratori current work commerci
scale-up activ track juli launch clear abl suppli
entir market hypopen product launch given gener posit percept
auto-injector deliveri method simpli patient- caregiver-friendli option versu pre-
fill syring believ launch gvoke product drive gvoke franchis critic
mass dovetail feedback recent physician survey see detail
page
illustr usabl gvoke auto-injector hypopen
xeri aim support commerci effort via direct-to-consum dtc campaign
includ tv ad mid-major market high glucagon volum presenc
key social media outlet compani launch dtc campaign begin januari
citi notabl manag plan initi addit dtc project follow launch
hypopen prescrib front recal around rep personnel place
call cde certifi diabet educ physician current account
glucagon prescript sale team support medic affair director
could envis expans sale forc road presenc gvoke
franchis grow bear mind note sale infrastructur current
around half reach infrastructur
encourag earli data point gvoke access regard payer front coverag
encompass commerci live note month gvoke
prefer unrestrict access commerci plan encompass approxim
commerci live prefer unrestrict access medicar part plan encompass
commerci live encourag data point view given product
commerci avail sinc novemb regard remain commerci live
gvoke essenti either non-pref posit without restrict non-pref posit
restrict patient constrain specifi network physician
receiv coverag manag cite goal continu increas
page
conduct brief survey physician manag signific number insulin-
depend diabet patient familiar baqsimi gvoke sever hypoglycemia
rescu primari goal gaug physician percept current avail glucagon
rescu product name glucagon kit baqsimi gvoke regard gvoke mainli focus
hypopen given expect present account lion share volum
survey respond point prescrib glucagon emerg kit
insulin-depend diabet patient regard physician percept glucagon kit
respond note kit either moder difficult patient caregiv
use anoth note kit slightli difficult use given backdrop hope gain
addit insight extent physician prescrib behavior glucagon product might
impact avail baqsimi gvoke respond note
plan prescrib glucagon product insulin-depend diabet patient either moder
significantli frequent next year
regard physician percept gvoke specif hypopen rel baqsimi note
respond believ pen present either moder significantli better
option baqsimi nasal spray anoth believ pen slightli better
option anoth respond state auto-injector pen present
good method administr baqsimi nasal spray term prescrib behavior
respond note plan prescrib gvoke injector pen anywher slightli
significantli frequent basqsimi plan prescrib gvoke frequent
baqsimi given feedback believ competit landscap prove
zero-sum game gvoke baqsimi
regard prescrib behavior gvoke specif hypopen absolut sens
half respond state plan prescrib hypopen either slight major
signific major insulin-depend type type diabet patient feedback
whole speak highli recept audienc gvoke view speak ampl
room gvoke baqsimi co-exist thrive commerci though
page
clearli gvoke pen present drive gvoke-rel enthusiasm surpris
given advantag pen present rel pre-fil syring present
histor prescrib glucagon inject kit glucagon emerg kit
insulin-depend diabet patient
current avail glucagon emerg kit packag glucagon vial requir
prepar inject prior administr measur dilut
product prior inject given backdrop pleas choos one follow
regard view difficulti patient self-administr caregiv
administr inject current avail glucagon emerg kit sever
page
xeri gvoke ready-to-us inject glucagon product avail pre-
fill syring injector pen form gvoke becom avail later
baqsimi nasal spray form glucagon neither product requir measur
mix dilut ready-to-us given avail gvoke
baqsimi sever hypoglycemia rescu pleas choos one follow
regard extent plan prescrib glucagon product overal
insulin-depend diabet patient next year
xeri gvoke ready-to-us inject glucagon product avail pre-
fill syring xeri expect launch injector pen known hypopen version
product later eli lilli baqsimi nasal spray form glucagon neither product
requir measur mix dilut ready-to-us given
backdrop pleas choos one follow regard view mode
administr gvoke injector pen baqsimi nasal spray
page
base understand gvoke injector pen baqsimi nasal spray
glucagon administr sever hypoglycemia insulin-depend diabet patient
pleas choos one follow regard extent plan
prescrib gvoke injector pen rel baqsimi nasal spray
pleas choos one follow regard futur prescrib behavior
gvoke injector pen next year
page
base expect glucagon market grow consider addit
novel deliveri technolog gvoke baqsimi coupl clear limit associ
glucagon emerg kit believ gvoke baqsimi ampl room co-
exist also thrive commerci put anoth way envis zero-sum-gam
two product regard recent trend lilli report baqsimi net sale
first full-quart market trx
run product week data
gvoke peak sale realist view model reflect gvoke sale grow
near nearli eu bear mind
mention compani plan submit file eu end
model reflect sizabl gross-to-net spread given larg underli patient
popul payer contract fact life model reflect steady-st
low-to-mid time model reflect launch hypopen reflect total
gvoke rx translat net sale model
reflect rx net sale
gvoke prescript includ pre-fil syring hypopen auto-injector form auto-injector launch expect juli
gvoke pre-fil syring suppli packag either pre-fil syring concentr ml mg/ml glucagon subcutan inject wholesal acquisit
cost wac per syring concentr
cite current market volum unit glucagon per prescript
wac hypopen auto-injector product pre-filled syring
compani report iqvia wolter kluwer pricerx psc estim
xeri current evalu gvoke two phase ii studi one sever hypoglycemia follow
bariatr surgeri diabet patient exercise-induc hypoglycemia eih
studi includ in-pati out-pati compon out-pati stage patient
random gvoke placebo week xeri recent announc posit data in-
patient stage studi data out-pati stage expect later
xeri two addit inject product earli clinic develop xeri
expect data in-pati portion phase ii studi evalu co-formul
pramlintid insulin patient type diabet xeri also evalu inject
form anti-seizur drug diazepam patient acut repetit seizur phase ib data
expect
page
sale salesglucagon emerg kit prescript rx sequenti sequenti glucagon prescript exclud sequenti total prescript rx per pre-fil syring pre-fil syring per rx per rx realiz price per exhibit
xeri develop pipelin upcom mileston
label expans opportun post-bariatr surgeri hypoglycemia bariatr surgeri
gastric bypass weight-loss relat surgeri becom rel common procedur
note bariatr surgeri perform year us post-
bariatr surgeri patient hypoglycemia uncommon incid patient per
year per manag commentari difficult condit treat carbohydr alon
given overcompens lead subsequ hyperglycemia event post-bariatr
hypoglycem event typic occur hour eat
given backdrop xeri studi gvoke random phase ii trial patient
approv product would first avail ready-to-us glucagon therapi outpati use
set regard gvoke studi phase ii trial contain two-visit in-pati stage
follow out-pati stage portion studi patient random
receiv mini-dos mch ready-to-us glucagon gvoke placebo specif
patient self-administ product placebo experi hypoglycemia symptom
 anxieti nausea sweat tremor palpit blood glucos level measur
minut minut administr
decemb xeri report data in-pati portion studi in-pati stage
involv two in-clin visit includ meal challeng typic follow
event within minut result studi show mcg glucos suffici
maintain return blood glucos normal level within minut administr
durat effect minut incid rebound hypoglycem event
lower gvoke-tr patient versu placebo lastli treatment emerg advers event teae
similar placebo product safe well toler seriou advers event
sae observ note out-pati portion studi on-going data
expect
label expans opportun exercise-induc hypoglycemia eih beyond post-bariatr
surgeri hypoglycemia also common complic insulin-depend diabet patient
period vigor exercis due fact insulin level rise substanti
result addit glucos intak muscl adipos liver cell given insulin-
depend diabet patient theoret risk hypoglycemia eih repres sizabl
page
expans opportun gvoke recal diabet patient current
insulin manag note signific unmet need set
given diabet patient current must go multipl prepar step prior exercis
 insulin pump reduct hour exercis addit recommend patient
increas carbohydr intak substanti prior exercis
given backdrop xeri studi gvoke random placebo-control phase ii trial
eih patient like studi eih phase ii trial contain two-visit in-pati stage follow
out-pati stage studi patient self-administ mini-dos mcg
gvoke placebo immedi prior exercis addit treatment group placebo
group reduc insulin intak pump prior exercis blood glucos level
measur minut follow start exercis session
note xeri report data in-pati portion studi januari result show
gvoke-tr patient experienc fewer hypoglycem event versu placebo addit
mini-dos gvoke suffici restor maintain normal blood glucos level patient
eih follow moderate-to-sever aerob exercis final number placebo patient
request glucos tablet restor blood glucos level higher gvoke treat patient
incid treatment emerg advers event similar placebo product
safe well toler seriou advers event sae observ
out-pati portion studi current on-going specif out-pati studi
open-label trial addit two in-pati group describ third
treatment group receiv gvoke without insulin pump reduct note data
out-pati stage expect
pramlintid brief pramlintid peptid mimic amylin hormon like insulin amylin
co-secret pancrea regul blood glucos level insulin respons
clear glucos blood circul meal amylin regul glucos level blood
circul inhibit glucagon secret delay gastric empti put anoth way amylin
insulin work togeth maintain healthi glycem level mealtim
astrazeneca symlin pramlintid combin insulin approv fda
regul glycem level patient diabet note two treatment must
deliv separ due incompat natur solut despit well-known benefit
pramlintid underutil physician patient due fact involv addit
given backdrop xeri develop liquid-st ready-to-us solut decreas
treatment burden pramlintid diabet patient follow posit safeti bioavail data
phase studi xeri initi random open-label single-dos phase ii studi
septemb divid in-pati stage out-pati stage evalu
efficaci pharmacokinet pharmacodynam pramlintid insulin co-formul
versu separ insulin pramlintid inject xeri current enrol patient studi
phase ii data expect note extent program yield favor
result almost certainli look partner asset given full-on insulin
develop program would entail high degre spend mention commerci
resourc need support new insulin-contain formul
diazepam brief diazepam benzodiazepin commonli known trade name valium act
gabaa receptor central nervou system induc anxiolyt anticonvuls
amnest effect vein diazepam commonli use treat epilepsi anxieti disord
per manag commentari epilepsi impact roughli patient epilepsi
page
patient world-wide common neurolog problem
 patient current around epilepsi patient suffer acut repetit
seizur ar character patient experienc seizur within given
hour period ar also known cluster seizur
recent approv diazepam formul diazepam current standard-of-car
option manag cluster seizur commonli use diazepam formul
diastat acudi avail rectal gel though obviou limit associ
administr rectal formul seizur given backdrop
understand diastat mainli use pediatr patient penetr product
gener low valium oral form product rel slow act limit
given difficulti associ take oral product onset seizur final
oral liquid form diazepam also avail treat cluster seizur limit
oral solid form valium
regard commerci avail diazepam product note neureliss valtoco
single-us diazepam nasal spray seizur cluster epilept patient age
approv fda januari
pen pre-fil syring form diazepam would use addit ar treatment
landscap xeri develop form diazepam intramuscular inject im epilept
patient cluster seizur note xeri report posit data random open-
label crossov studi phase studi patient may result studi show
im inject mg im formul safe well toler rel diastat
xeriss product demonstr higher exposur compar equival dose diastat
xeri obtain orphan drug design ar dravet syndrom respect
regard develop manag note function capit resourc
extent abbrevi pathway market full-
blown phase studi compani may put develop hold period time surmis
would attract asset develop in-hous extent reason
effici path market given highli concentr natur physician audienc would
requir dramat invest sale forc headcount
paul edick chairman chief execut offic mr edick join
chairman chief execut offic januari prior xeri mr edick found
advisor consult pharmaceut healthcar healthcar investor
commun chief execut offic durata therapeut drtx
biopharmaceut compani address grow need new antibiot treat infecti
diseas mr edick also extens industri experi lead consum
pharmaceut healthcar organ includ pharmacia group vice presid
presid asia pacif latin america oper pharmacia mr edick current serv
chairman board mileston pharmaceut inc previous serv number
pharmaceut healthcar compani board includ iterum therapeut itrm
neo newlink genet inc
nlnk mr edick hold bachelor art psycholog hamilton colleg
scott prestrelski ph co-founder chief scienc offic dr prestrelski founder
chief scientif offic addit dr prestrelski also inventor
xeri platform technolog intern recogn expert drug formul
deliveri year product develop experi prior join xeri dr prestrelski
vice presid amylin dr prestrelski
publish invit book chapter peer-review journal articl issu
pend patent applic field drug formul deliveri dr prestrelski
phd molecular biophys citi univers new york master busi
administr radi school manag univers california san diego
page
john shannon chief oper offic mr shannon current serv chief oper offic
xeri pharmaceut mr shannon year pharmaceut healthcar
experi recent mr shannon spent year chief execut offic cathet
connect inc prior cathet connect mr shannon spent year chief commerci
offic durata therapeut mr shannon spent year baxter healthcar
gener manag global hemophilia global commerci excel gener
manag vice presid market us bioscienc vice presid
market us renal time baxter led commerci drove growth
baxter brand advat gammagard exceed revenu billion
dollar mr shannon bachelor scienc biolog emphasi microbiolog
ken johnson pharm senior vice presid clinic develop regulatori qualiti
medic affair dr johnson current serv senior vice presid
clinic develop regulatori qualiti assur medic affair
dr johnson respons lead effort effect gener high-qual scientif
clinic evid xeri product support product approv advanc clinic educ
practic inform polici improv health outcom patient dr johnson
year profession experi pharmaceut industri pharmaceut benefit
manag academia dr johnson recent execut director us medic affair
hospit specialti product merck dr johnson receiv doctor pharmaci
univers minnesota complet postdoctor fellowship univers tennesse
health scienc center dr johnson hold number adjunct academ appoint
member sever profession societi
beth hecht senior vice presid gener counsel corpor secretari beth
hecht serv senior vice presid gener counsel corpor secretari xeri
pharmaceut year experi corpor execut life scienc
industri recent serv manag director chief legal administr offic
auven global biotechnolog pharmaceut privat equiti firm beth also
member board director neo chair
nomin govern committe ms hecht graduat amherst colleg harvard
law school start career attorney special intellectu properti corpor
transact willki farr gallagh ny kirkland elli ny establish
led legal complianc licens human resourc secur depart compani
includ sun product medpoint inc formerli known carter-wallac
inc warner chilcott plc chirex ltd alpharma inc
allison wey senior vice presid investor relat corpor commun ms
wey serv senior vice presid investor relat corpor commun
bring year experi investor relat corpor commun media relat
invest bank xeri prior join xeri ms wey serv vice presid investor
relat corpor commun
pharmaceut prior posit ms wey vice-president investor relat boron lepor
associ senior vice presid edelman world-wide manag director
commun hill knowlton associ director equiti capit market bear stearn
 co inc ms wey graduat drake univers
kevin mcculloch senior vice presid global oper busi develop
kevin mcculloch join octob senior vice presid global
oper busi develop mr mcculloch spent year
pharmaceut medic devic industri divers leadership gener manag role
span sale market busi oper us intern entiti prior
join xeri kevin presid global solut hill-rom earlier chief busi
offic water street healthcar partner pharmaceut hold mr mcculloch spent
year baxter healthcar success manag role includ gm/presid global
servic global fluid system gf infus system fenwal busi unit mr
mcculloch hold mba univers kellogg school manag
bachelor degre biolog univers michigan
page
xeri quarterli annual incom statement
million except ep
sale
incom loss tax
expens total product sale
gener administr
proprietari piper sandler februari
current disclosur inform compani found http //www pipersandl com/researchdisclosur
